ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Japanese OTC drugmakers enlarging footprint in Asia

Takeda has begun selling its Alinamin vitamins in Hong Kong.

TOKYO -- Takeda Pharmaceutical and other Japanese drugmakers are broadening their over-the-counter business overseas as burgeoning inbound demand by foreign tourists boosts brand recognition.

     Takeda is laying the groundwork for exporting its mainstay Alinamin vitamins to mainland China, aiming for a launch within the next three years pending government approval and other potential delays. Among other places, the company made inroads in Thailand in 2014 and in South Korea and Hong Kong the next year.

     The drugmaker will spin off the over-the-counter segment, hoping to have it up and running in April of next year. Overseas sales of Alinamin are pegged as a growth pillar, with the company eyeing Vietnam and India as future markets.

     Another Japanese pharmaceutical maker, Ryukakusan, will begin marketing in Taiwan a jelly used to help children take medicine as early as this summer. Next year, the company will start exporting a throat medicine to Taiwan and Hong Kong.

     Tokyo-based drug companies Kinkan and Yamazaki Teikokudo are also mulling expansions to Hong Kong and Vietnam within three years.

     Foreign tourists to Japan are purchasing roughly 40 billion yen ($352 million) in nonprescription medicine annually, according to industry figures, indicating that Japanese manufacturers enjoy healthy name recognition in Asia. Companies are playing catch-up to Taiko Pharmaceutical and Taisho Pharmaceutical Holdings, which each generate about 20% of sales in foreign markets.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media